STOCK TITAN

CELL SOURCE (CLCS) Financials

CLCS OTC
Trailing 12 months to March 31, 2025
Revenue Not reported for the trailing 12 months
Net Income Not reported for the trailing 12 months
EPS (Diluted) -$0.14 FY2024 annual
Operating Cash Flow -$3.1M n/m YoY
Market Cap $31.6M as of Oct 27, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m no net income reported
Price / Book n/m negative shareholder equity, so no book multiple, Q1 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2025, ended Mar 31, 2025 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2025, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLCS SEC filings page.

This page shows CELL SOURCE INC (CLCS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLCS FY2024

Liabilities dominate the balance sheet, while shrinking assets and negative equity point to a financing-dependent development business.

Between FY2021 and FY2024, liabilities rose 85.6% even as assets fell 8.7%, so financing obligations expanded without a comparable asset base. That structure left FY2024 liabilities at $18.8M against $287K of assets and negative equity, making the balance sheet the central operating fact.

Research spending accelerated, rising 52.5% in FY2021 and another 52.2% in FY2022. With revenue unreported, the filings depict spending before demonstrated commercial scale rather than a revenue-funded operating model.

Assets fell from $410K in FY2022 to $195K in FY2023, then recovered to $287K in FY2024. Because liabilities still rose 19.1% in FY2024, the asset rebound did not restore balance-sheet strength.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

CELL SOURCE INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)
-$0.04
YoYn/m

CELL SOURCE INC earned -$0.04 per diluted share (EPS) in Q1 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Revenue

Not reported for Q1 2025.

EBITDA

Not reported for Q1 2025.

Net Income

Not reported for Q1 2025.

Cash & Balance Sheet

Cash & Debt
$1K
YoY+5291.3%
QoQ-98.3%

CELL SOURCE INC held $1K in cash as of Q1 2025; no long-term debt figure is on record for that period.

Shares Outstanding
45M
YoY+9.8%
QoQ0.0%

CELL SOURCE INC had 45M shares outstanding in Q1 2025. This represents an increase of 9.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2025.

Dividends Per Share

Not reported for Q1 2025.

Margins & Returns

None of these metrics is reported for Q1 2025.

Capital Allocation

None of these metrics is reported for Q1 2025.

CLCS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLCS quarterly income statement
MetricQ1'2510-QQ4'2410-QQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-QQ2'2310-Q
SG&A Expenses$483KN/A$471K-2.1%$374K-30.8%N/AN/A$481K-9.9%$540K
Operating Income-$999KN/A-$832Kn/m-$1.2Mn/mN/AN/A-$995Kn/m-$905K
Net IncomeN/AN/AN/A-$1.5Mn/mN/AN/AN/A-$1.2M
EPS (Basic)-$0.04n/mN/A-$0.04n/m-$0.04n/m-$0.04n/m-$0.03n/m-$0.04n/m-$0.04n/m
EPS (Diluted)-$0.04n/mN/A-$0.04n/m-$0.04n/m-$0.04n/m-$0.03n/m-$0.04n/m-$0.04n/m
Diluted Shares (Avg)45M+11.2%N/A42M+11.1%41M+10.2%41M+9.3%N/A38M+8.4%37M+8.1%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Interest Expense, Income Tax.

CLCS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLCS quarterly balance sheet
MetricQ1'2510-QQ4'2410-QQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-QQ2'2310-Q
Total Assets$292K+254.1%$287K+46.8%$265K+6.6%$430K+18.6%$83K-64.5%$195K-52.4%$248K-31.1%$362K+711.7%
Cash & Equivalents$1K+5291.3%$75K+236.1%$23K+790.5%$91K+311.7%$23-100.0%$22K-90.0%$3K-96.1%$22K+746.9%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$20.4M+21.3%$18.8M+19.1%$19.2M+18.0%$17.7M+15.9%$16.8M+16.5%$15.8M+21.2%$16.3M+32.2%$15.3M+41.6%
Total Equity-$20.1Mn/m-$18.5Mn/m-$18.9Mn/m-$17.3Mn/m-$16.8Mn/m-$15.6Mn/m-$16.0Mn/m-$14.9Mn/m
Retained Earnings-$47.7Mn/m-$46.2Mn/m-$45.8Mn/m-$44.4Mn/m-$42.9Mn/m-$41.7Mn/m-$40.6Mn/m-$39.3Mn/m

Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.

CLCS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLCS quarterly cash flow statement
MetricQ1'2510-QQ4'2410-QQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-QQ2'2310-Q
Operating Cash Flow-$600Kn/m-$748Kn/m-$639Kn/m-$1.1Mn/m-$174Kn/m-$722Kn/m-$280Kn/m-$1.0M
Stock-Based Compensation$104K-63.8%N/A$5K-80.5%$15K-69.4%$289K-12.2%N/A$26K-65.3%$50K+67617.6%
Financing Cash Flow$527K+247.5%$800K+7.8%$571K+119.3%$1.2M+31.2%$152K-31.0%$742K-15.7%$261K-77.3%$925K+440.4%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

CLCS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLCS quarterly financial ratios
MetricQ1'2510-QQ4'2410-QQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-QQ2'2310-Q
Return on AssetsN/AN/AN/A-346.4%-3.7ppN/AN/AN/A-342.7%

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Current Ratio, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$18.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
CELL SOURCE INC CLCS FY2024 N/A N/A N/A $31.6M —
ONCOTELIC THERAPEUTCS INC OTLC FY2025 N/A $249.3M N/A $8.6M —
ACCUSTEM SCIENCES INC ACUT FY2025 N/A -$1.8M N/A $2.4M —

Frequently Asked Questions

What is CELL SOURCE INC's earnings per share (EPS)?

CELL SOURCE INC (CLCS) reported diluted earnings per share of -$0.14 for fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What are CELL SOURCE INC's total assets?

CELL SOURCE INC (CLCS) had $287K in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does CELL SOURCE INC have outstanding?

CELL SOURCE INC (CLCS) had 45M shares outstanding as of fiscal year 2024.

CELL SOURCE INC (CLCS) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $31.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

CELL SOURCE INC (CLCS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $31.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

CELL SOURCE INC (CLCS) has negative shareholder equity of -$18.5M as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Back to top